Biovaxys Technology Corp (BVAXF)

$0.12 +0.01 (9.00%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 251,459
Avg Vol 42,728
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 56%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell...

Industry: Biotechnology
Sector: Healthcare
Phone: 740-358-0555
Address:
146 Thirtieth Street, Suite 100, Etobicoke, Canada
ProfitWhisperer
ProfitWhisperer Jul. 23 at 3:56 PM
$BVAXF $BIOV.CSE Two separate timelines on BIOV. Audit backlog and Form 7 catch-up are what actually matter for trading resumption. Filing completion moves the needle, milestone confirmation is secondary. Platform science gets properly valued once compliance clears.
0 · Reply
Ventureville
Ventureville Jul. 22 at 5:39 PM
$BIOV.CSE $BVAXF now has two competing narratives: encouraging Phase 1 platform data and an immediate financial-reporting problem. Resolution of the filing delay is the next catalyst the market needs before the science can be properly valued. $MRNA $BNTX
1 · Reply
ProfitWhisperer
ProfitWhisperer Jul. 22 at 4:25 PM
$BVAXF $BIOV.CSE Moffitt Cancer Center work showing DPX advantage is real. Single formulation with 14+ neoantigens generates stronger CD8+ T-cell response than aqueous formulations or peptide pools. Platform validation moving into product development. Clinical evidence over marketing language. https://x.com/biovaxys/status/2079637122777063581
0 · Reply
CptCotton
CptCotton Jul. 22 at 12:28 AM
$BVAXF yall think someone is gonna buy this company anytime soon? I am getting worried
2 · Reply
wheresdannynow
wheresdannynow Jul. 21 at 4:04 PM
$BVAXF Phase 1 results gave $BIOV $BVAXF another clinical validation point for DPX-formulated products. For a platform biotech, reproducible human data matter more than pipeline quantity. $IOVA $MRNA $BNTX
0 · Reply
wheresdannynow
wheresdannynow Jul. 21 at 4:03 PM
$BVAXF The latest clinical update strengthens the scientific case for the DPX platform. $BIOV.CSE now needs regulatory execution, financing clarity and a development partner to unlock that value. $MRNA $BNTX $CVAC
0 · Reply
wheresdannynow
wheresdannynow Jul. 21 at 4:02 PM
$BVAXF $BIOV.CSE setup is binary but clear: promising human data on one side, financing and reporting risk on the other. Resolution of the filings could become as important as the next clinical announcement. $MRNA $CVAC
0 · Reply
ProfitWhisperer
ProfitWhisperer Jul. 21 at 3:52 PM
$BVAXF $BIOV.CSE Cancer vaccines aren't just antigens. Delivery system matters most. DPX sustains immune exposure long enough to generate durable, antigen-specific T-cell responses. This is the competitive advantage. Platform extends across multiple indications once clinical validation stacks.
0 · Reply
jconnors7
jconnors7 Jul. 20 at 5:12 PM
$BVAXF
0 · Reply
wheresdannynow
wheresdannynow Jul. 20 at 4:36 PM
$BVAXF The most important catalyst for $BIOV.CSE $BVAXF is not another pipeline announcement. It is clinical evidence showing durable immune activation, tumor response and acceptable safety. $IOVA $MRNA $BNTX
0 · Reply
Latest News on BVAXF
No data available.
ProfitWhisperer
ProfitWhisperer Jul. 23 at 3:56 PM
$BVAXF $BIOV.CSE Two separate timelines on BIOV. Audit backlog and Form 7 catch-up are what actually matter for trading resumption. Filing completion moves the needle, milestone confirmation is secondary. Platform science gets properly valued once compliance clears.
0 · Reply
Ventureville
Ventureville Jul. 22 at 5:39 PM
$BIOV.CSE $BVAXF now has two competing narratives: encouraging Phase 1 platform data and an immediate financial-reporting problem. Resolution of the filing delay is the next catalyst the market needs before the science can be properly valued. $MRNA $BNTX
1 · Reply
ProfitWhisperer
ProfitWhisperer Jul. 22 at 4:25 PM
$BVAXF $BIOV.CSE Moffitt Cancer Center work showing DPX advantage is real. Single formulation with 14+ neoantigens generates stronger CD8+ T-cell response than aqueous formulations or peptide pools. Platform validation moving into product development. Clinical evidence over marketing language. https://x.com/biovaxys/status/2079637122777063581
0 · Reply
CptCotton
CptCotton Jul. 22 at 12:28 AM
$BVAXF yall think someone is gonna buy this company anytime soon? I am getting worried
2 · Reply
wheresdannynow
wheresdannynow Jul. 21 at 4:04 PM
$BVAXF Phase 1 results gave $BIOV $BVAXF another clinical validation point for DPX-formulated products. For a platform biotech, reproducible human data matter more than pipeline quantity. $IOVA $MRNA $BNTX
0 · Reply
wheresdannynow
wheresdannynow Jul. 21 at 4:03 PM
$BVAXF The latest clinical update strengthens the scientific case for the DPX platform. $BIOV.CSE now needs regulatory execution, financing clarity and a development partner to unlock that value. $MRNA $BNTX $CVAC
0 · Reply
wheresdannynow
wheresdannynow Jul. 21 at 4:02 PM
$BVAXF $BIOV.CSE setup is binary but clear: promising human data on one side, financing and reporting risk on the other. Resolution of the filings could become as important as the next clinical announcement. $MRNA $CVAC
0 · Reply
ProfitWhisperer
ProfitWhisperer Jul. 21 at 3:52 PM
$BVAXF $BIOV.CSE Cancer vaccines aren't just antigens. Delivery system matters most. DPX sustains immune exposure long enough to generate durable, antigen-specific T-cell responses. This is the competitive advantage. Platform extends across multiple indications once clinical validation stacks.
0 · Reply
jconnors7
jconnors7 Jul. 20 at 5:12 PM
$BVAXF
0 · Reply
wheresdannynow
wheresdannynow Jul. 20 at 4:36 PM
$BVAXF The most important catalyst for $BIOV.CSE $BVAXF is not another pipeline announcement. It is clinical evidence showing durable immune activation, tumor response and acceptable safety. $IOVA $MRNA $BNTX
0 · Reply
wheresdannynow
wheresdannynow Jul. 20 at 4:35 PM
$BVAXF Cancer vaccines are not simply about identifying an antigen. The delivery system must sustain immune exposure long enough to produce a meaningful cellular response. That is the technical angle behind $BIOV $BVAXF. $BNTX $MRNA
0 · Reply
wheresdannynow
wheresdannynow Jul. 20 at 4:35 PM
$BVAXF thesis is platform validation. If DPX can consistently generate durable, antigen-specific T-cell responses, the opportunity extends beyond a single cancer indication. $MRNA $BNTX $CVAC
0 · Reply
ProfitWhisperer
ProfitWhisperer Jul. 20 at 3:45 PM
$BVAXF $BIOV.CSE 75 days into the halt, well past the 61-day precedent from 2024. Platform validation thesis solid. Bladder data hitting, Tartaglia joining, DPX acquisition complete. Real question is when filings clear. Post-halt re-rating should follow execution.
0 · Reply
JanetBSmellin
JanetBSmellin Jul. 17 at 7:05 PM
$BVAXF doubled my shares at .05. I can’t believe it!
0 · Reply
ProfitWhisperer
ProfitWhisperer Jul. 17 at 3:39 PM
$BVAXF $BIOV.CSE MVP-S data reading across ovarian and bladder. Platform versatility positioning BIOV for multiple value drivers long-term. MCTO overhang is temporary noise. Data keeps validating. Watching for post-filing re-rate when overhang clears and data holds. Multiple should catch up to pipeline breadth eventually.
0 · Reply
Davidendz
Davidendz Jul. 17 at 2:25 PM
$BVAXF Cancer vaccines have historically struggled with weak or short-lived immune activation. The $BIOV $BVAXF thesis rests on whether DPX can generate persistent, therapeutically relevant T-cell responses. $BNTX $MRNA $CVAC
0 · Reply
Davidendz
Davidendz Jul. 17 at 2:25 PM
$BVAXF $BIOV.CSE $BVAXF is pursuing an out-licensing model, which could reduce internal commercialization requirements. The tradeoff is dependence on partner interest, deal structure and milestone execution. $LGND $RPRX $MRNA
0 · Reply
Davidendz
Davidendz Jul. 17 at 2:24 PM
$BVAXF Strong clinical momentum from MVP-S combos in ovarian/bladder + platform versatility positions BIOV well long-term. MCTO overhang temporary; data de-risks the story. Watching for post-filing re-rating. $BIOV.CSE
0 · Reply
ProfitWhisperer
ProfitWhisperer Jul. 16 at 3:15 PM
$BVAXF $BIOV.CSE 3 dated proof points. Breast cancer readout Dec, bladder data July, SpayVac already showing 89% fertility reduction with Zoetis published. Program outline in and data validating on schedule. Market probably has not caught up yet. Watching for next readout to confirm trend before sizing up.
0 · Reply
Ventureville
Ventureville Jul. 15 at 6:42 PM
$BVAXF I love this stock because the new bladder cancer data is hitting responses even after other treatments failed. DPX just works.
0 · Reply
ProfitWhisperer
ProfitWhisperer Jul. 15 at 5:12 PM
$BVAXF $BIOV.CSE Platform validation thesis is solid, but the 21.4M share reserve against 44M outstanding is a 49% dilution overhang. Once filings clear, if management immediately raises to fund SpayVac, oncology, biodefense, mRNA programs all at once, that eats into the reward. Let's watch the dilution math carefully.
0 · Reply
FLArnot
FLArnot Jul. 14 at 7:52 PM
$BVAXF That 2 year chart says a lot about then gaining IMV's assets. Either the asset isn't what the hype says or management is failing miserably. With the CTO I think it is obvious which is failing.
0 · Reply